Terphenyl-Based Bak Bh3 Alpha-Helical Proteomimetics As Low-Molecular-Weight Antagonists Of Bcl-X-L

Hang Yin,Gui-in Lee,Kristine A. Sedey,Olaf Kutzki,Hyung Soon Park,brendan patrick orner,Justin T. Ernst,Hong-Gang Wang,Said M. Sebti,Andrew D. Hamilton
DOI: https://doi.org/10.1021/ja050122x
IF: 15
2005-01-01
Journal of the American Chemical Society
Abstract:We describe a general method for the mimicry of one face of an a-helix based on a terphenyl scaffold that spatially projects functionality in a manner similar to that of two turns of an a-helix. The synthetic scaffold reduces the flexibility and molecular weight of the mimicked protein secondary structure. We have applied this design to the development of antagonists of the a-helix binding protein Bcl-x(L). Using a sequential synthetic strategy, we have prepared a library of terphenyl derivatives to mimic the helical region of the Bak BH3 domain that binds Bcl-x(L). Fluorescence polarization assays were carried out to evaluate the ability of terphenyl derivatives to displace the Bcl-x(L)-bound Bak peptide. Terphenyl 14 exhibited good in vitro affinity with a K-i value of 0.114 mu M. These terphenyl derivatives were more selective at disrupting the Bcl-x(L)/Bak over the HDM2/p53 interaction, which involves binding of the N-terminal alpha-helix of p53 to HDM2. Structural studies using NMR spectroscopy and computer-aided docking simulations suggested that the helix binding area on the surface of Bcl-x(L) is the target for the synthetic ligands. Treatment of human embryonic kidney 293 (HEK293) cells with terphenyl derivatives resulted in the disruption of the binding of Bcl-x(L) to Bax in intact cells.
What problem does this paper attempt to address?